Business Description
PharmAbcine Inc
ISIN : KR7208340000
Share Class Description:
XKRX:208340: Ordinary SharesCompare
Compare
Traded in other countries / regions
208340.Korea IPO Date
2018-11-21Description
PharmAbcine Inc is a clinical stage biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.67 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.26 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.58 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.8 | |||||
| 3-Year EBITDA Growth Rate | 24.6 | |||||
| 3-Year EPS without NRI Growth Rate | 28.4 | |||||
| 3-Year FCF Growth Rate | 27.9 | |||||
| 3-Year Book Growth Rate | -37.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 52.41 | |||||
| 14-Day RSI | 54.82 | |||||
| 6-1 Month Momentum % | 20.21 | |||||
| 12-1 Month Momentum % | 2.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.46 | |||||
| Quick Ratio | 5.46 | |||||
| Cash Ratio | 4.72 | |||||
| Days Sales Outstanding | 139.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.4 | |||||
| Shareholder Yield % | 0.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -8380.23 | |||||
| Net Margin % | -10023.22 | |||||
| FCF Margin % | -7775.89 | |||||
| ROE % | -69.06 | |||||
| ROA % | -39.75 | |||||
| ROIC % | -58 | |||||
| ROC (Joel Greenblatt) % | -486.65 | |||||
| ROCE % | -56.14 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 659.8 | |||||
| PB Ratio | 5.69 | |||||
| Price-to-Tangible-Book | 5.79 | |||||
| EV-to-EBIT | -6.24 | |||||
| EV-to-EBITDA | -6.8 | |||||
| EV-to-Revenue | 662.47 | |||||
| EV-to-FCF | -8.52 | |||||
| Price-to-Net-Current-Asset-Value | 9.36 | |||||
| Price-to-Net-Cash | 11.97 | |||||
| Earnings Yield (Greenblatt) % | -16.03 | |||||
| FCF Yield % | -9.97 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers